Navigation Links
EORTC study shows value of HRQOL assessment in small cell lung cancer
Date:1/28/2014

An EORTC study published in Lancet Oncology found that health-related quality of life (HRQOL) assessment in small-cell lung cancer randomized clinical trials provides relevant added information in studies where the treatment arms do not differ in terms of efficacy. More importantly, it provides valuable information for those treatments where better HRQOL is associated with overall survival benefit. The study also found that even though the overall standard for reporting health-related quality of life was acceptable, there is still need for improvement regarding its reporting in randomized clinical trials to optimize their value.

There were an estimated 410,000 new cases of lung cancer and 353,000 deaths in Europe in 2012. Small-cell lung cancer accounts for roughly 15% of all lung cancers, and most small-cell lung cancer patients present with advanced disease. Consequently, disease management and treatment focuses on symptom control and health-related quality of life. In randomized clinical trials, health-related quality of life of small-cell lung cancer is now being evaluated more frequently.

The objective of this EORTC study was to evaluate the adequacy of health-related quality of life methodology reporting in small-cell lung cancer randomized clinical trials and the possible impact of this on clinical decision making. The study concerned randomized clinical trials that implemented patient-reported health-related quality of life assessments and oncology treatments for adult small-cell lung cancer patients (18 years of age or older), were completed between January 1991 and December 2012, included 100 or more patients, and were published in English. Over 10,000 patients were classified as eligible for this study from 30 randomized clinical trials out of an initial pool of 79 studies found.

The EORTC study found that HRQOL was a secondary endpoint in 29 RCTs of which 53% reported no significant difference in overall survival (OS). A difference of HRQOL was reported in 77% of the positive-outcome trials, and in 50% of the negative-outcome trials. A priori hypothesis on the expected overall HRQOL outcome was defined in 27% of the RCTs. Baseline HRQOL assessment was stated as mandatory in 14% of the RCTs. Tests of statistical significance were applied in 90% of the RCTs and missing data were discussed in detail in 30% of the trials.

Dr. Andrew Bottomley, EORTC Assistant Director and an author of this study says, "The EORTC has been a leader in establishing standards for conducting systematic reviews of patient reported outcomes in oncology randomized clinical trials. Arguably, the most important point about science is if results are reproducible. We have seen, time and again in over a decade of systematic literature research, that our results are consistent. We hope our quality of life research program has been useful in obtaining robust clinical research results, that these can be interpreted with confidence, and that decision makers can accept these findings from clinical trials in oncology. We hope our research has led others to use the EORTC Patient Reported Outcomes Checklist to design and evaluate other clinical trials and ensure high quality HRQOL."


'/>"/>
Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Related medicine news :

1. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
2. EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
3. EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
4. Markers in Cancer, a joint meeting by ASCO, EORTC & NCI, 7-9 Nov 2013 (diagnostic tutorial on 5-7)
5. EORTC study shows radiotherapy and surgery provide regional control for breast cancer patients
6. EORTC BOS 2 trial opens for patients with resectable liver metastases from colorectal cancer
7. EORTC intergroup trial opens for patients with resected head of pancreas adenocarcinoma
8. EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer
9. Moderate dose radiotherapy effective in EORTC trial for patients with desmoid-type fibromatosis
10. EORTC at 2013 ECCO-ESMO-ESTRO meeting in Amsterdam
11. Vaccination with GM2-KLH-QS21 does not improve outcome of melanomas patients in EORTC study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology: